Revelyx获数千万美元A轮投资，重组A型肉毒液体制剂在海外开展II期临床｜早起看早期

Group 1 - Revelyx Bio Inc. has recently completed a multi-million dollar Series A financing round led by NRL Capital, with funds aimed at advancing clinical research and commercial expansion of its products globally [3] - The company, established in Delaware in 2025, has exclusive rights to a recombinant botulinum toxin type A liquid formulation (003) in overseas markets, excluding mainland China and certain regions [3][4] - The 003 formulation is currently undergoing Phase II clinical trials in Australia, with plans to apply for Phase III trials by 2026, initially targeting glabellar lines and potentially expanding to upper limb spasticity [3][4] Group 2 - The NewCo model allows Chinese pharmaceutical companies to license their product pipelines to newly established companies, receiving cash and equity compensation, which helps mitigate risks and accelerate overseas market expansion [4] - The investment strategy focuses on a few core products with international competitive advantages, maximizing resource allocation to enhance product value [4] - The production of botulinum toxin has evolved from complex fermentation processes to recombinant technologies, which offer advantages in safety, reliability, and product purity [5][6] Group 3 - The liquid pre-filled formulation of botulinum toxin is designed for ease of use, aiming for higher concentration and lower injection volume, which could enhance the duration of anti-aging effects [6] - NRL Capital's healthcare team believes that the recombinant botulinum toxin liquid formulation will provide superior efficacy, safety, and lower immunogenicity, while overcoming resistance issues [6]